Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis

被引：0
作者：
G. B. Gomez
D. W. Dowdy
M. L. Bastos
A. Zwerling
S. Sweeney
N. Foster
A. Trajman
M. A. Islam
S. Kapiga
E. Sinanovic
G. M. Knight
R. G. White
W. A. Wells
F. G. Cobelens
A. Vassall
机构：
[1] Academic Medical Center,Amsterdam Institute for Global Health and Development and Department of Global Health
[2] University of Amsterdam,Department of Global Health and Development
[3] London School of Hygiene and Tropical Medicine,Department of Epidemiology
[4] Johns Hopkins Bloomberg School of Public Health,TB Modelling Group, Department of Infectious Disease Epidemiology
[5] Federal University of Rio de Janeiro,undefined
[6] Tuberculosis Scientific League,undefined
[7] Health Economics Unit,undefined
[8] School of Public Health & Family Medicine,undefined
[9] University of Cape Town,undefined
[10] McGill University,undefined
[11] BRAC Health Nutrition and Population Programme,undefined
[12] BRAC Centre,undefined
[13] Mwanza Intervention Trials Unit,undefined
[14] National Institute for Medical Research,undefined
[15] London School of Hygiene and Tropical Medicine,undefined
[16] Global Alliance for TB Drug Development,undefined
[17] KNCV Tuberculosis Foundation,undefined
[18] Present address: United States Agency for International Development,undefined
来源：
BMC Infectious Diseases | / 16卷
关键词：
Tuberculosis; Cost-effectiveness; Economic evaluation; New technologies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 198 条
[1]  
Lienhardt C(2010)New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes Curr Opin Pulm Med 16 186-93
[2]  
Vernon A(2014)Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 18 810-7
[3]  
Raviglione MC(2014)Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis N Engl J Med 371 1577-87
[4]  
Gospodarevskaya E(2014)Multidrug-resistant tuberculosis and culture conversion with bedaquiline N Engl J Med 371 723-32
[5]  
Tulloch O(2012)Delamanid for multidrug-resistant pulmonary tuberculosis N Engl J Med 366 2151-60
[6]  
Bunga C(2012)14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Lancet 380 986-93
[7]  
Ferdous S(2013)Cost-effectiveness of novel first-line treatment regimens for tuberculosis Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 17 590-6
[8]  
Jonas A(2006)Prospects for advancing tuberculosis control efforts through novel therapies PLoS Med 3 13980-5
[9]  
Islam S(2009)Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics Proc Natl Acad Sci U S A 106 S231-279
[10]  
Gillespie SH(2014)Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis PloS One 9 230-4
12345678910